Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07543731
A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab
Sponsor: Novartis Pharmaceuticals
View on ClinicalTrials.gov
Summary
This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.
Official title: Real-World Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab in Italy
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
OBSERVATIONAL
Enrollment
5995
Start Date
2026-04-02
Completion Date
2026-10-30
Last Updated
2026-07-15
Healthy Volunteers
No
Conditions
Locations (1)
Novartis
Basel, Switzerland